Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.88 |
| ▸ | NPC1 | O15118 | 7/20 | 0.88 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.88 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MGAM | O43451 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | SI | P14410 | 4/20 | 0.62 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538920 | 0.97 | RAB9A (0.94) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL16479583 | 0.88 | RAB9A (0.78) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL3107207 | 0.87 | RAB9A (0.76) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL17713905 | 0.86 | KDM4E (0.76) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6539262 | 0.86 | KDM4E (0.97) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL21156447 | 0.85 | RAB9A (0.74) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL12939777 | 0.85 | RAB9A (0.74) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL21157737 | 0.85 | RAB9A (0.73) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL8742518 | 0.84 | RAB9A (0.72) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL8742494 | 0.84 | RAB9A (0.72) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-9085600-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2014-04-03 | — | — | US | disclosed |
| US-8470985-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| CN-1240713-C | New compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-02-08 | — | — | CN | disclosed |
| CN-1296494-A | New compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-05-23 | — | — | CN | disclosed |
| US-6232290-B1 | FUNGICIDES AGAINST PNEUMOCYSTIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| EP-1053247-A1 | ANTIFUNGAL CYCLOHEXAPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | RAB9A 2624/4885MAPT 4213/4885LMNA 2857/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | RAB9A 1747/4885MAPT 4552/4885LMNA 2404/4885 |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | PROKR1, ARG1, ARG2 | RAB9A 2624/4885MAPT 4213/4885LMNA 2857/4885 |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | RAB9A 2624/4885MAPT 4213/4885LMNA 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.